Dravet syndrome

pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms

Jun 18, 2024

Takeda Showcase Phase III Results for Soticlestat; Imfinzi and Chemotherapy Combination Gains US Approval; Nipocalimab Shows Notable Efficacy in Phase II Study; Bristol Myers Squibb’s Augtyro FDA Approval; AstraZeneca’s Farxiga FDA Approval

Latest Pharma News for VistaGen and Merck

Jul 26, 2022

VistaGen’s PH94B for Anxiety Disorder; Keytruda for Head and Neck Cancer Treatment; Bavarian Nordic’s Smallpox Vaccine Imvanex; CAMP4 Raises USD 100 Million; Incyte’s WU-CART-007; Incyte’s Opzelura for Vitiligo; AstraZeneca and Merck’s Lynparza; Sumitomo Pharma’s DSP-0390 for Brain Cancer

Dravet Syndrome Market | Dravet Syndrome Pipeline

Aug 28, 2020

The Rarity Of Dravet Syndrome: Challenges, and Treatments

pharma-news

Apr 30, 2020

Remdesivir accelerates for COVID-19 recovery; Merck pact with Almac; Pfizer, BioNTech finish dosing in; Taysha Gene Therapies for trials

Marijuana

Jan 08, 2020

Marijuana as a treatment approach

MEDICAL MARIJUANA

Apr 03, 2019

What can be the scope of Medical Marijuana?

Sep 30, 2016

The Snippet: The Success of Cannabidiol

Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper
Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper

Newsletter/Whitepaper